Ahlqvist-Rastad Jane, Albertsson Maria, Bergh Jonas, Birgegård Gunnar, Johansson Peter, Jonsson Bertil, Kjellen Elisabeth, Påhlman Sven, Zackrisson Björn, Osterborg Anders
Medical Products Agency, Uppsala 751 03, Sweden.
Med Oncol. 2007;24(3):267-72. doi: 10.1007/s12032-007-0037-5.
Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
由于对促红细胞生成素（EPO）治疗及其对肿瘤控制可能产生的负面影响存在担忧，瑞典医疗产品管理局组织了一次研讨会，目的是在必要时修订国家治疗指南。在实体瘤患者中，关于肿瘤控制和生存率的报道结果相互矛盾。因此，在另行通知之前，建议在癌症患者治疗中限制使用EPO，并且应根据潜在风险评估预期的生活质量改善情况。
